The “Hyperuricemia (Metabolic Disorder) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Hyperuricemia – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 6, 2, 5 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.
Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)
Key Topics Covered:
Hyperuricemia – Overview
- Hyperuricemia – Therapeutics Development
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Hyperuricemia – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Hyperuricemia – Companies Involved in Therapeutics Development
- Allena Pharmaceuticals Inc
- Arthrosi Therapeutics Inc
- AstraZeneca Plc
- FortuneRock (China) Ltd
- Fuji Yakuhin Co Ltd
- Hangzhou Grand Biologic Pharmaceutical Inc
- Hinova Pharmaceuticals Inc
- InventisBio Inc
- J-Pharma Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Nippon Chemiphar Co Ltd
- NuBioPharma LLC
- PegBio Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shanton Pharma Co Ltd
- Stealth Biologics LLC
- Suzhou Sinovent Pharmaceuticals Co Ltd
- Teijin Pharma Ltd
- Xiuzheng Pharmaceutical Group Co Ltd
Hyperuricemia – Drug Profiles
- (allopurinol +verinurad) – Drug Profile
- ABP-671 – Drug Profile
- ALLN-346 – Drug Profile
- allopurinol – Drug Profile
- AR-882 – Drug Profile
- D-0120 – Drug Profile
- febuxostat – Drug Profile
- HP-501 SR – Drug Profile
- HZBio-1 – Drug Profile
- JPH-367 – Drug Profile
- JS-103 – Drug Profile
- NC-2500 – Drug Profile
- NC-2700 – Drug Profile
- PB-348 – Drug Profile
- Recombinant Enzyme for Gout and Hyperuricemia – Drug Profile
- Recombinant Urate Oxidase Replacement for Acute Hyperuricemia – Drug Profile
- SAP-001 – Drug Profile
- SFR-9350 – Drug Profile
- SHR-4640 – Drug Profile
- Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile
- Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
- Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
- taininade – Drug Profile
- TMX-049 – Drug Profile
- topiroxostat – Drug Profile
- verinurad – Drug Profile
- XNW-3009 – Drug Profile
- YL-90148 – Drug Profile
Hyperuricemia – Dormant Projects
Hyperuricemia – Discontinued Products
Hyperuricemia – Product Development Milestones
Featured News & Press Releases
- Jul 12, 2021: Allena Pharmaceuticals provides update on ALLN-346 clinical development program
- Mar 05, 2021: Shanghai Junshi Bioscience announces JS103 Injection received the acceptance notice for the investigational new drug application
- Nov 30, 2020: Allena Pharmaceuticals announces initial data from phase 1 trial of ALLN-346
- Sep 08, 2020: Allena Pharmaceuticals doses first subject in phase 1 clinical trial of ALLN-346, in development for the treatment of Hyperuricemia in patients with gout and advanced chronic kidney disease
For more information about this report visit https://www.researchandmarkets.com/r/ycxhh3
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900